Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences to Host Webcast Event on Schizophrenia
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Minerva
View HTML
Toggle Summary Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in 2019  Management to host conference call today at 8:30 a.m.
View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
Management to host conference call WALTHAM, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the filing of a U.S.
View HTML
Toggle Summary Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
WALTHAM, Mass. , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Evercore ISI
View HTML
Toggle Summary Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial   All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals   Tested
View HTML
Toggle Summary Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
WALTHAM, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London
View HTML
Toggle Summary Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
View HTML
Toggle Summary Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
Management to host conference call WALTHAM, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML